AZYO - Aziyo Biologics, Inc. Stock Price, Fair Value and News

Market Closed

AZYO Stock Price

View Fullscreen

AZYO RSI Chart

AZYO Valuation

Market Cap

34.9M

Price/Earnings (Trailing)

-0.73

Price/Sales (Trailing)

1.2

EV/EBITDA

-0.99

Price/Free Cashflow

-1.81

AZYO Price/Sales (Trailing)

AZYO Profitability

EBT Margin

-178.63%

Return on Equity

94.79%

Return on Assets

-134.82%

Free Cashflow Yield

-55.4%

AZYO Fundamentals

AZYO Revenue

Revenue (TTM)

29.0M

Rev. Growth (Yr)

-48.7%

Rev. Growth (Qtr)

13.94%

AZYO Earnings

Earnings (TTM)

-47.7M

Earnings Growth (Yr)

-125.66%

Earnings Growth (Qtr)

-93.19%

Breaking Down AZYO Revenue

Last 7 days

-4.6%

Last 30 days

-33.0%

Last 90 days

-36.2%

Trailing 12 Months

-80%

How does AZYO drawdown profile look like?

AZYO Financial Health

Current Ratio

0.63

Debt/Equity

-0.39

Debt/Cashflow

-0.97

AZYO Investor Care

Shares Dilution (1Y)

48.07%

Diluted EPS (TTM)

-2.33

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	29.0M	0	0	0
2023	38.1M	35.8M	36.1M	35.3M
2022	24.5M	28.5M	32.5M	36.6M
2021	45.7M	49.3M	49.0M	20.5M
2020	42.8M	42.8M	42.7M	42.7M
2019	0	0	0	42.9M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Aziyo Biologics, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Jun 21, 2023	mills c randal	sold (taxes)	-18,730	2.41	-7,772	president and ceo
Jun 21, 2023	mills c randal	acquired	-	-	22,474	president and ceo
Apr 27, 2023	mills c randal	acquired	-	-	44,947	president and ceo
Mar 27, 2023	birchview capital, lp	bought	15,870	1.587	10,000	-
Mar 24, 2023	birchview capital, lp	bought	27,078	1.3539	20,000	-
Mar 23, 2023	birchview capital, lp	bought	164,010	1.491	110,000	-
Mar 09, 2023	englese thomas	sold	-1,242	4.3	-289	chief commercial officer
Mar 08, 2023	englese thomas	acquired	-	-	937	chief commercial officer
Mar 08, 2023	ferguson matthew	acquired	-	-	1,287	chief financial officer
Dec 15, 2022	colpman david	bought	12,082	3.9	3,098	-

Which funds bought or sold AZYO recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	BANK OF AMERICA CORP /DE/	added	471,580	74,279	74,290	-%
May 15, 2024	SILVERARC CAPITAL MANAGEMENT, LLC	new	-	247,527	247,527	0.07%
May 15, 2024	Tower Research Capital LLC (TRC)	added	37.88	8,351	16,613	-%
May 15, 2024	Nantahala Capital Management, LLC	reduced	-50.00	-1,930,500	5,197,500	0.30%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	reduced	-8.18	15,518	61,293	-%
May 15, 2024	Royal Bank of Canada	added	117	1,000	1,000	-%
May 14, 2024	NORTHERN TRUST CORP	added	3.64	14,718	43,498	-%
May 14, 2024	Knollwood Investment Advisory, LLC	added	594	1,161,690	1,289,050	0.23%
May 14, 2024	AIGH Capital Management LLC	reduced	-74.32	-2,296,820	1,375,180	0.41%
May 14, 2024	Qube Research & Technologies Ltd	unchanged	-	1.00	3.00	-%

Are Funds Buying or Selling AZYO?

Are funds buying AZYO calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own AZYO

No. of Funds

Unveiling Aziyo Biologics, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 20, 2024	birchview capital, lp	8.76%	1,655,184	SC 13G/A
Feb 14, 2024	nantahala capital management, llc	9.9%	1,912,776	SC 13G
Feb 07, 2024	hirschman orin	9.9%	1,886,556	SC 13G/A
Oct 06, 2023	highcape capital, l.p.	0.3%	48,931	SC 13D/A
Apr 07, 2023	birchview capital, lp	13.9%	1,655,184	SC 13G/A
Mar 21, 2023	endurant capital management lp	4.88%	576,253	SC 13G/A
Feb 14, 2023	endurant capital management lp	10.67%	1,259,544	SC 13G/A
Feb 14, 2023	endurant capital management lp	10.67%	1,259,544	SC 13G/A
Feb 13, 2023	birchview capital, lp	12.8%	1,515,184	SC 13G/A
Dec 15, 2022	birchview capital, lp	12.7%	1,502,123	SC 13G/A

Recent SEC filings of Aziyo Biologics, Inc.

View All Filings

Date Filed	Form Type	Document
May 13, 2024	10-Q	Quarterly Report
May 09, 2024	8-K	Current Report
Apr 22, 2024	DEFA14A	DEFA14A
Apr 22, 2024	DEF 14A	DEF 14A
Apr 01, 2024	8-K	Current Report
Mar 14, 2024	4	Insider Trading
Mar 11, 2024	10-K	Annual Report
Mar 07, 2024	8-K	Current Report
Feb 20, 2024	SC 13G/A	Major Ownership Report
Feb 20, 2024	4/A	Insider Trading

Aziyo Biologics, Inc. News

Latest updates

Aziyo Biologics, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																			(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3
Revenue	13.9%	6,694,000	5,875,000	6,127,000	10,296,000	13,050,000	6,587,000	5,849,000	12,638,000	11,495,000	11,490,000	11,485,000	12,160,000	12,884,000	12,466,000	11,774,000	8,579,000	9,863,000	10,500,500	11,138,000
Gross Profit	87.8%	2,843,000	1,513,500	2,841,000	980,000	6,331,000	1,293,500	2,939,000	4,898,000	4,281,000	-6,352,000	3,689,000	5,614,000	6,329,000	6,021,000	5,541,000	3,784,000	5,215,000	-	5,543,000
Operating Expenses	18.0%	11,322,000	9,593,500	10,212,000	10,065,000	12,749,000	11,616,000	11,906,000	13,080,000	11,203,000	6,907,000	10,665,000	10,209,000	10,028,000	9,984,000	8,232,000	7,547,000	-	-	-
S&GA Expenses	70.4%	3,309,000	1,942,000	2,802,000	3,618,000	5,356,000	3,712,500	4,379,000	5,406,000	4,818,000	2,370,000	4,783,000	4,799,000	4,703,000	4,720,000	4,301,000	4,062,000	4,482,000	-	4,435,000
R&D Expenses	4.1%	1,172,000	1,125,500	557,000	1,171,000	1,803,000	1,487,500	1,723,000	2,617,000	2,272,000	1,864,000	2,289,000	1,881,000	1,720,000	1,973,000	1,264,000	1,408,000	1,309,000	-	507,000
EBITDA Margin	-61.2%	-1.46	-0.91	-0.67	-0.75	-0.68	-0.72	-1.06	-1.11	-1.00	-1.04	-0.24	-0.21	-0.28	-0.29	-0.06	-0.06	-0.06	-0.06	-
Interest Expenses	-5.9%	1,313,000	1,395,500	1,448,000	1,524,000	1,544,000	1,452,000	1,247,000	1,204,000	1,215,000	1,290,000	1,328,000	1,351,000	1,355,000	1,385,000	1,465,000	1,410,000	1,373,000	-	1,249,000
Income Taxes	200.0%	8,000	-8,000	12,000	12,000	12,000	-2,000	12,000	12,000	12,000	12,000	12,000	18,000	13,000	8,000	8,000	5,000	5,000	-	8,000
Earnings Before Taxes	-22.5%	-17,986,000	-14,686,500	-8,507,000	-10,609,000	-7,962,000	-6,812,500	-11,017,000	-9,386,000	-8,137,000	-14,549,000	-8,304,000	-2,367,000	-5,054,000	-5,348,000	-6,723,000	-5,173,000	-4,555,000	-	-3,096,000
EBT Margin	-51.2%	-1.79	-1.18	-0.94	-1.02	-0.92	-0.97	-1.32	-1.42	-1.36	-1.48	-0.43	-0.40	-0.49	-0.51	-0.28	-0.28	-0.28	-0.28	-
Net Income	-93.2%	-17,994,000	-9,314,000	-9,747,000	-10,621,000	-7,974,000	-5,440,000	-9,910,000	-9,398,000	-8,149,000	-9,064,000	-8,316,000	-2,385,000	-5,067,000	-5,356,000	-6,731,000	-5,178,000	-4,560,000	-	-3,104,000
Net Income Margin	-54.4%	-1.64	-1.07	-0.94	-0.95	-0.86	-0.90	-1.12	-1.22	-1.14	-1.21	-0.43	-0.40	-0.49	-0.51	-0.28	-0.28	-0.28	-0.28	-
Free Cashflow	71.3%	-2,615,000	-9,100,000	-5,140,000	-2,485,000	-5,382,000	-5,379,000	-1,944,000	-10,955,000	-7,384,000	-6,412,000	-3,195,000	-903,000	-5,305,000	-5,483,000	-1,665,000	-4,018,000	-3,100,000	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2019Q4
Assets	-18.6%	35.00	43.00	55.00	52.00	61.00	69.00	61.00	53.00	60.00	67.00	60.00	70.00	74.00	83.00	46.00	45.00
Current Assets	-23.3%	24.00	31.00	39.00	36.00	43.00	51.00	44.00	35.00	41.00	47.00	39.00	48.00	52.00	60.00	22.00	18.00
Cash Equivalents	-34.9%	13.00	19.00	15.00	9.00	12.00	17.00	8.00	17.00	22.00	30.00	23.00	28.00	30.00	40.00	2.00	3.00
Inventory	-20.8%	3.00	4.00	7.00	9.00	11.00	4.00	10.00	10.00	10.00	3.00	10.00	10.00	10.00	10.00	10.00	7.00
Net PPE	-0.6%	0.00	0.00	0.00	1.00	1.00	0.00	1.00	1.00	1.00	0.00	1.00	1.00	1.00	1.00	1.00	1.00
Liabilities	4.4%	86.00	82.00	84.00	74.00	73.00	74.00	72.00	54.00	53.00	54.00	52.00	55.00	58.00	62.00	64.00	55.00
Current Liabilities	-11.5%	38.00	43.00	45.00	43.00	41.00	43.00	40.00	35.00	27.00	26.00	23.00	24.00	25.00	27.00	26.00	18.00
Short Term Borrowings	-31.5%	2.00	3.00	-	-	-	-	-	8.00	8.00	8.00	8.00	8.00	9.00	6.00	3.00	2.00
Long Term Debt	-3.0%	20.00	20.00	25.00	25.00	25.00	24.00	20.00	7.00	9.00	10.00	12.00	14.00	16.00	18.00	21.00	20.00
LT Debt, Non Current	-100.0%	-	20.00	25.00	25.00	25.00	24.00	20.00	7.00	9.00	10.00	12.00	14.00	16.00	18.00	21.00	20.00
Shareholder's Equity	-30.3%	-50.30	-38.60	-	-	-12.17	-5.03	-	-	7.00	14.00	8.00	15.00	16.00	21.00	-	-
Retained Earnings	-10.2%	-193	-175	-166	-156	-145	-137	-132	-122	-113	-105	-96.03	-87.71	-85.33	-80.26	-74.90	-56.94
Additional Paid-In Capital	4.6%	143	137	137	134	134	133	122	121	120	119	104	103	102	101	-	2.00
Shares Outstanding	31.7%	24.00	18.00	16.00	16.00	16.00	14.00	14.00	14.00	14.00	10.00	10.00	10.00	10.00	3.00	1.00	1.00
Float	-	-	-	-	15.00	-	-	-	31.00	-	-	-	29.00	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																			(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3
Cashflow From Operations	71.4%	-2,600	-9,083	-5,078	-2,400	-5,200	-5,245	-1,827	-10,700	-7,350	-6,387	-3,098	-787	-5,174	-5,368	-1,229	-3,991	-3,038	-	-
Share Based Compensation	388.2%	2,197	450	616	687	684	774	298	1,470	1,105	973	1,000	885	677	595	58.00	72.00	54.00	-	-
Cashflow From Investing	-100.1%	-15.00	14,537	-62.00	-85.00	-182	-134	-117	-255	-34.00	-25.00	-97.00	-116	-131	-115	-436	-27.00	-62.00	-	-
Cashflow From Financing	-485.5%	-4,069	-695	10,406	-19.00	148	14,267	-2,320	-3,000	-869	14,214	-2,547	-1,230	-3,726	43,371	2,269	4,432	1,136	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

AZYO Income Statement

2024-03-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
Net sales	$ 6,694	$ 6,392
Cost of goods sold	3,851	3,018
Gross profit	2,843	3,374
Sales and marketing	3,309	4,691
General and administrative	5,056	3,520
Research and development	1,172	1,591
FiberCel litigation costs, net	1,785	1,911
Total operating expenses	11,322	11,713
Loss from operations	(8,479)	(8,339)
Interest expense	1,313	1,430
Loss on revaluation of warrant liability	9,637
Gain on revaluation of revenue interest obligation	(1,443)
Loss before provision for income taxes	(17,986)	(9,769)
Income tax expense	8	12
Net loss from continuing operations	(17,994)	(9,781)
Income from discontinued operations		1,807
Net loss	$ (17,994)	$ (7,974)
Net loss from continuing operations per share - basic (in dollars per share)	$ (0.75)	$ (0.61)
Net loss from continuing operations per share - diluted (in dollars per share)	(0.75)	(0.61)
Net income from discontinued operations per share - basic (in dollars per share)		0.11
Net income from discontinued operations per share - diluted (In dollars per share)		0.11
Net loss - basic (in dollar per share)	(0.75)	(0.49)
Net loss - diluted (in dollar per share)	$ (0.75)	$ (0.49)
Weighted average common shares outstanding - basic (in shares)	23,912,326	16,149,567
Weighted average common shares outstanding - diluted (in shares)	23,912,326	16,149,567

AZYO Balance Sheet

2024-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash	$ 12,551	$ 19,276
Accounts receivable, net	4,406	3,263
Inventory	3,052	3,853
Receivables of litigation costs	2,031	2,696
Prepaid expenses and other current assets	1,946	2,165
Total current assets	23,986	31,253
Property and equipment, net	171	172
Intangible assets, net	10,822	11,671
Operating lease right-of-use assets and other	383	332
Total assets	35,362	43,428
Current liabilities:
Accounts payable	4,156	2,285
Accrued expenses	9,022	9,485
Payables to tissue suppliers	907	906
Current portion of long-term debt	2,274	3,321
Current portion of revenue interest obligation	5,900	11,741
Contingent liability for FiberCel litigation	15,591	15,024
Current operating lease liabilities	217	275
Total current liabilities	38,067	43,037
Long-term debt	19,738	20,356
Long-term revenue interest obligation	7,659	5,360
Warrant liability	19,503	12,760
Other long-term liabilities	694	515
Total liabilities	85,661	82,028
Commitments and contingencies
Stockholders' equity (deficit):
Additional paid-in capital	143,315	137,021
Accumulated deficit	(193,638)	(175,644)
Total stockholders' deficit	(50,299)	(38,600)
Total liabilities and stockholders' deficit	35,362	43,428
Class A Common stock
Stockholders' equity (deficit):
Common stock	20	19
Class B Common stock
Stockholders' equity (deficit):
Common stock	$ 4	$ 4

About Aziyo Biologics, Inc.

Aziyo Biologics, Inc. Frequently Asked Questions

What is the ticker symbol for Aziyo Biologics, Inc.? What does AZYO stand for in stocks?

AZYO is the stock ticker symbol of Aziyo Biologics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Aziyo Biologics, Inc. (AZYO)?

As of Sun Mar 31 2024, market cap of Aziyo Biologics, Inc. is 34.91 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AZYO stock?

You can check AZYO's fair value in chart for subscribers.

What is the fair value of AZYO stock?

You can check AZYO's fair value in chart for subscribers. The fair value of Aziyo Biologics, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Aziyo Biologics, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AZYO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Aziyo Biologics, Inc. a good stock to buy?

The fair value guage provides a quick view whether AZYO is over valued or under valued. Whether Aziyo Biologics, Inc. is cheap or expensive depends on the assumptions which impact Aziyo Biologics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AZYO.

What is Aziyo Biologics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Sun Mar 31 2024, AZYO's PE ratio (Price to Earnings) is -0.73 and Price to Sales (PS) ratio is 1.2. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AZYO PE ratio will change depending on the future growth rate expectations of investors.